Chronic Kidney Disease <-> Gout

Comorbidity A_BEFORE_B CANDIDATE

The kidney sets the serum urate level, so a disease of the kidney and a disease of urate crystal deposition are mechanistically adjacent by construction. Directionality is recorded as A_BEFORE_B because that is the direction the evidence actually supports: reduced renal urate excretion is the dominant hyperuricemic mechanism in gout, and incident gout is common when patients with stage 3-5 CKD and asymptomatic hyperuricemia are followed forward. The reverse direction is curated explicitly as a *refuted* hypothesis rather than left implicit. Hyperuricemia and gout are consistently associated with CKD in observational data, which invites the inference that urate is nephrotoxic and that lowering it protects the kidney — but a 13-year population cohort found no difference in incident CKD between urate-lowering therapy users and non-users. Recording that negative result here is the point of the entry: it stops the observational association from being read as a bidirectional causal loop. Two confounders run through everything in this pair and are not separated by the sources cited: diuretics raise urate and are prescribed to exactly this population, and CKD, hypertension and gout share metabolic antecedents. The cohort below reports diuretic use as an independent predictor of incident gout within the CKD population, which is a treatment-mediated route rather than a direct kidney-to-joint mechanism. Within CKD, incident gout does not rise with kidney-disease severity. The same cohort reports gout in 21.3% of stage 3, 14.9% of stage 4 and 3.9% of stage 5 patients, and lower serum creatinine as an independent predictor (HR 0.81 per 1 mg/dL). The authors attribute the inverse gradient to competing mortality in advanced CKD, blunted monocyte cytokine responses to urate crystals in end-stage renal disease, and larger urate fluctuations in earlier CKD. The directed claim here is therefore that CKD is an antecedent state that raises urate, not that gout risk scales with renal failure.

Disease A

Chronic Kidney Disease

Slug:Chronic_Kidney_Disease

Disease B

Gout

Slug:Gout

Causal Mechanism Graphs

Chronic Kidney Disease

graph LR
    SGLT2_Inhibitors["SGLT2 Inhibitors"]
    Anemia["Anemia"]
    Creatinine["Creatinine"]
    Proteinuria["Proteinuria"]
    Peripheral_Edema["Peripheral Edema"]
    Dialysis["Dialysis"]
    Tubulointerstitial_Fibrosis["Tubulointerstitial Fibrosis"]
    AAV_Mediated_Klotho_Gene_Therapy["AAV-Mediated Klotho Gene Therapy"]
    NMR_metabolomic_risk_score_MetRS["NMR metabolomic risk score (MetRS)"]
    IL_11_Signalling_in_Renal_Fibroblasts["IL-11 Signalling in Renal Fibroblasts"]
    Decreased_GFR["Decreased GFR"]
    Blood_Pressure_Control["Blood Pressure Control"]
    Klotho_Deficiency["Klotho Deficiency"]
    Hypertension["Hypertension"]
    RAAS_Activation["RAAS Activation"]
    Dietary_Protein_Restriction["Dietary Protein Restriction"]
    Fatigue["Fatigue"]
    Nephron_Loss["Nephron Loss"]
    Kidney_Transplantation["Kidney Transplantation"]
    Glomerulosclerosis["Glomerulosclerosis"]
    Metabolic_Acidosis["Metabolic Acidosis"]
    ACE_Inhibitors_ARBs["ACE Inhibitors/ARBs"]
    Tubular_and_Podocyte_Mesenchymal_Drift["Tubular and Podocyte Mesenchymal Drift"]

    Nephron_Loss --> Decreased_GFR
    Nephron_Loss --> Metabolic_Acidosis
    Nephron_Loss --> Glomerulosclerosis
    Glomerulosclerosis --> Proteinuria
    Glomerulosclerosis --> Nephron_Loss
    Klotho_Deficiency --> Tubulointerstitial_Fibrosis
    Klotho_Deficiency --> IL_11_Signalling_in_Renal_Fibroblasts
    IL_11_Signalling_in_Renal_Fibroblasts --> Tubulointerstitial_Fibrosis
    Tubular_and_Podocyte_Mesenchymal_Drift --> Tubulointerstitial_Fibrosis
    Tubulointerstitial_Fibrosis --> Anemia
    Tubulointerstitial_Fibrosis --> Nephron_Loss
    RAAS_Activation --> Hypertension
    RAAS_Activation --> Peripheral_Edema
    RAAS_Activation --> Tubulointerstitial_Fibrosis
    Anemia --> Fatigue
    ACE_Inhibitors_ARBs --> RAAS_Activation
    SGLT2_Inhibitors --> Tubulointerstitial_Fibrosis
    Blood_Pressure_Control --> Glomerulosclerosis
    Dietary_Protein_Restriction --> Glomerulosclerosis
    Dialysis --> Nephron_Loss
    Kidney_Transplantation --> Nephron_Loss
    AAV_Mediated_Klotho_Gene_Therapy --> Klotho_Deficiency
    Nephron_Loss -.-> Creatinine
    Nephron_Loss -.-> NMR_metabolomic_risk_score_MetRS

    style SGLT2_Inhibitors fill:#fce7f3
    style Anemia fill:#fef3c7
    style Creatinine fill:#e0e7ff
    style Proteinuria fill:#fef3c7
    style Peripheral_Edema fill:#fef3c7
    style Dialysis fill:#fce7f3
    style Tubulointerstitial_Fibrosis fill:#dbeafe
    style AAV_Mediated_Klotho_Gene_Therapy fill:#fce7f3
    style NMR_metabolomic_risk_score_MetRS fill:#e0e7ff
    style IL_11_Signalling_in_Renal_Fibroblasts fill:#dbeafe
    style Decreased_GFR fill:#fef3c7
    style Blood_Pressure_Control fill:#fce7f3
    style Klotho_Deficiency fill:#dbeafe
    style Hypertension fill:#dcfce7
    style RAAS_Activation fill:#dbeafe
    style Dietary_Protein_Restriction fill:#fce7f3
    style Fatigue fill:#fef3c7
    style Nephron_Loss fill:#dbeafe
    style Kidney_Transplantation fill:#fce7f3
    style Glomerulosclerosis fill:#dbeafe
    style Metabolic_Acidosis fill:#fef3c7
    style ACE_Inhibitors_ARBs fill:#fce7f3
    style Tubular_and_Podocyte_Mesenchymal_Drift fill:#dbeafe

Gout

graph LR
    Complement_Activation["Complement Activation"]
    Hyperuricemia["Hyperuricemia"]
    Neutrophil_Extracellular_Trap_Formation["Neutrophil Extracellular Trap Formation"]
    Inflammasome_Activation["Inflammasome Activation"]
    Joint_Swelling["Joint Swelling"]
    Beer_Intake["Beer Intake"]
    Minimal_Urate_Homeostasis_Model["Minimal Urate Homeostasis Model"]
    Shellfish_Intake["Shellfish Intake"]
    ABCG2["ABCG2"]
    SLC22A12["SLC22A12"]
    SLC2A9["SLC2A9"]
    Crystal_Deposition["Crystal Deposition"]
    Joint_Pain["Joint Pain"]
    Nephrolithiasis["Nephrolithiasis"]
    Acute_Arthritis["Acute Arthritis"]
    Neutrophil_Recruitment["Neutrophil Recruitment"]
    Serum_Uric_Acid["Serum Uric Acid"]
    Red_Meat_and_Organ_Meat_Intake["Red Meat and Organ Meat Intake"]
    Fructose_Sweetened_Soft_Drink_Intake["Fructose-Sweetened Soft Drink Intake"]

    Hyperuricemia --> Crystal_Deposition
    Hyperuricemia --> Nephrolithiasis
    Crystal_Deposition --> Inflammasome_Activation
    Inflammasome_Activation --> Neutrophil_Recruitment
    Inflammasome_Activation --> Complement_Activation
    Inflammasome_Activation --> Acute_Arthritis
    Neutrophil_Recruitment --> Neutrophil_Extracellular_Trap_Formation
    Neutrophil_Recruitment --> Joint_Pain
    Neutrophil_Recruitment --> Joint_Swelling
    Complement_Activation --> Neutrophil_Recruitment
    Neutrophil_Extracellular_Trap_Formation --> Acute_Arthritis
    Red_Meat_and_Organ_Meat_Intake --> Hyperuricemia
    Shellfish_Intake --> Hyperuricemia
    Beer_Intake --> Hyperuricemia
    Fructose_Sweetened_Soft_Drink_Intake --> Hyperuricemia
    Minimal_Urate_Homeostasis_Model --> Hyperuricemia
    Hyperuricemia -.-> Serum_Uric_Acid
    SLC2A9 --> Hyperuricemia
    ABCG2 --> Hyperuricemia
    SLC22A12 --> Hyperuricemia

    style Complement_Activation fill:#dbeafe
    style Hyperuricemia fill:#dbeafe
    style Neutrophil_Extracellular_Trap_Formation fill:#dbeafe
    style Inflammasome_Activation fill:#dbeafe
    style Joint_Swelling fill:#fef3c7
    style Beer_Intake fill:#dcfce7
    style Minimal_Urate_Homeostasis_Model fill:#ecfccb
    style Shellfish_Intake fill:#dcfce7
    style ABCG2 fill:#f3e8ff
    style SLC22A12 fill:#f3e8ff
    style SLC2A9 fill:#f3e8ff
    style Crystal_Deposition fill:#dbeafe
    style Joint_Pain fill:#fef3c7
    style Nephrolithiasis fill:#fef3c7
    style Acute_Arthritis fill:#fef3c7
    style Neutrophil_Recruitment fill:#dbeafe
    style Serum_Uric_Acid fill:#e0e7ff
    style Red_Meat_and_Organ_Meat_Intake fill:#dcfce7
    style Fructose_Sweetened_Soft_Drink_Intake fill:#dcfce7

Association Signals

Signal 1

Population:771 ambulatory non-dialysis patients with stage 3-5 chronic kidney disease and asymptomatic hyperuricemia (serum urate >=7.0 mg/dL) and no prior gout, single centre, followed 2010-2023 with a median follow-up of 47 months and incident gout confirmed by rheumatology specialists.

Mapping notes:The cohort is restricted to CKD patients who are already hyperuricemic, so the rate is conditioned on the intermediate step of the mechanism and is higher than it would be across unselected CKD. Single-centre and retrospective, as the authors note.

Temporal: A before B: , B before A: , Same time:

INCIDENCE_RATE: 41.9

CI: -

FDR:

Incident gout per 1,000 person-years; 140 of 771 patients (18.2%) over a median 47 months. The denominator is a CKD population followed forward with gout excluded at baseline, which is what the directed A_BEFORE_B claim requires.

PMID:41608294 (SUPPORT)

Source: HUMAN_CLINICAL

"gout developed in 140 (18.2%) patients (incidence rate, 41.9 cases per 1,000 person-years)."

Measures incident gout prospectively within a defined CKD cohort, supporting CKD as an antecedent state for gout rather than a co-diagnosis.

Hypotheses

Failing renal urate handling is the proximate cause of the hyperuricemia that precedes gout. Urate is filtered and then largely reabsorbed by transporters in the proximal tubule, and the steady-state serum level is set by the net balance of that reabsorption against secretion; when excretory capacity falls, serum urate rises until monosodium urate supersaturates and deposits in joints. On this account gout in CKD is not a coincidental second diagnosis but the articular readout of a renal excretory defect.

PMID:23318701 (SUPPORT)

Source: HUMAN_CLINICAL

"Reduced renal excretion of urate is the underlying hyperuricemic mechanism in the vast majority of gout patients; most of the genes that affect serum urate level (SUA) encode urate transport"

Identifies impaired renal urate excretion, not overproduction, as the dominant mechanism of hyperuricemia in gout, which is what makes kidney disease mechanistically upstream.

PMID:23318701 (SUPPORT)

Source: HUMAN_CLINICAL

"the prevalence of renal comorbidities in gout - hypertension, chronic kidney disease (CKD), and nephrolithiasis - is very high."

Establishes CKD as one of the highly prevalent renal comorbidities of gout, corroborating the pairing at the population level.

Pathophysiology:

Impaired renal urate excretion and hyperuricemia: Loss of functioning nephrons reduces net urate excretion, raising serum urate toward the saturation point at which monosodium urate crystals deposit in and around joints.

Biological processes:

PMID:23318701 (SUPPORT)

Source: HUMAN_CLINICAL

"baseline SUA appears to be set by the net balance of absorption and secretion across epithelial cells in the kidney and intestine."

States that the serum urate set point is determined by renal and intestinal handling, the process this node represents.

Serum urate as the graded driver of incident gout in CKD: Within a CKD population that is already hyperuricemic, the risk of developing clinical gout continues to scale with serum urate, indicating the urate level and not merely the presence of kidney disease is what drives crystal deposition.

PMID:41608294 (SUPPORT)

Source: HUMAN_CLINICAL

"Notably, each 1 mg/dL increase in baseline serum urate levels was associated with a 29% higher risk of developing gout, with a HR of 1.29 (95% CI, 1.14-1.46)."

Quantifies the graded, per-unit effect of serum urate on incident gout within a CKD cohort, supporting urate as the mediating variable.

PMID:41608294 (SUPPORT)

Source: HUMAN_CLINICAL

"The relatively low gout incidence in CKD stage 5, particularly in patients receiving hemodialysis, compared with CKD stages 3-4, may be due to reduced inflammatory cytokine production."

The same cohort found gout less often at stage 5 than at stages 3-4, with lower creatinine an independent predictor. This does not contradict urate as the driver: it shows that kidney-disease severity is not the graded variable, and the authors attribute the inverse gradient partly to blunted inflammatory responses in advanced CKD (see entry notes).

Reverse-direction hypothesis, recorded because it is widely assumed and not supported: that hyperuricemia and gout are themselves nephrotoxic, so that gout drives incident CKD and lowering urate would protect renal function. A 13-year population-based cohort comparing urate-lowering therapy users with matched non-users among gout patients found no difference in incident CKD. The negative result does not exclude a urate effect on established CKD progression, which the cited study did not test, but it does undercut the simple causal loop and is why this entry is directed rather than BIDIRECTIONAL.

PMID:34104091 (REFUTE)

Source: HUMAN_CLINICAL

"This population-based cohort study indicated that ULT is not associated with lower risk of CKD development."

Removing the hyperuricemia did not reduce incident CKD in gout patients (adjusted hazard ratio 0.97, 95% CI 0.88-1.07), arguing against urate as a causal driver of new-onset kidney disease.

Raw YAML

Show YAML

name: com_Chronic_Kidney_Disease__Gout
creation_date: "2026-08-27T00:00:00Z"
curation_status: CANDIDATE
notes: >-
  The kidney sets the serum urate level, so a disease of the kidney and a
  disease of urate crystal deposition are mechanistically adjacent by
  construction. Directionality is recorded as A_BEFORE_B because that is the
  direction the evidence actually supports: reduced renal urate excretion is
  the dominant hyperuricemic mechanism in gout, and incident gout is common
  when patients with stage 3-5 CKD and asymptomatic hyperuricemia are followed
  forward.

  The reverse direction is curated explicitly as a *refuted* hypothesis rather
  than left implicit. Hyperuricemia and gout are consistently associated with
  CKD in observational data, which invites the inference that urate is
  nephrotoxic and that lowering it protects the kidney — but a 13-year
  population cohort found no difference in incident CKD between urate-lowering
  therapy users and non-users. Recording that negative result here is the point
  of the entry: it stops the observational association from being read as a
  bidirectional causal loop.

  Two confounders run through everything in this pair and are not separated by
  the sources cited: diuretics raise urate and are prescribed to exactly this
  population, and CKD, hypertension and gout share metabolic antecedents. The
  cohort below reports diuretic use as an independent predictor of incident
  gout within the CKD population, which is a treatment-mediated route rather
  than a direct kidney-to-joint mechanism.

  Within CKD, incident gout does not rise with kidney-disease severity. The
  same cohort reports gout in 21.3% of stage 3, 14.9% of stage 4 and 3.9% of
  stage 5 patients, and lower serum creatinine as an independent predictor
  (HR 0.81 per 1 mg/dL). The authors attribute the inverse gradient to
  competing mortality in advanced CKD, blunted monocyte cytokine responses to
  urate crystals in end-stage renal disease, and larger urate fluctuations in
  earlier CKD. The directed claim here is therefore that CKD is an antecedent
  state that raises urate, not that gout risk scales with renal failure.

disease_a:
  slug: Chronic_Kidney_Disease
  preferred_term: chronic kidney disease
  term:
    id: MONDO:0005300
    label: chronic kidney disease

disease_b:
  slug: Gout
  preferred_term: gout
  term:
    id: MONDO:0005393
    label: gout

directionality: A_BEFORE_B
effect_direction: RISK

hypotheses:
- description: >-
    Failing renal urate handling is the proximate cause of the hyperuricemia
    that precedes gout. Urate is filtered and then largely reabsorbed by
    transporters in the proximal tubule, and the steady-state serum level is
    set by the net balance of that reabsorption against secretion; when
    excretory capacity falls, serum urate rises until monosodium urate
    supersaturates and deposits in joints. On this account gout in CKD is not a
    coincidental second diagnosis but the articular readout of a renal
    excretory defect.
  evidence:
  - reference: PMID:23318701
    reference_title: The kidney in hyperuricemia and gout.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Reduced renal excretion of urate is the underlying hyperuricemic mechanism in the vast majority of gout patients; most of the genes that affect serum urate level (SUA) encode urate transport"
    explanation: >-
      Identifies impaired renal urate excretion, not overproduction, as the
      dominant mechanism of hyperuricemia in gout, which is what makes kidney
      disease mechanistically upstream.
  - reference: PMID:23318701
    reference_title: The kidney in hyperuricemia and gout.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the prevalence of renal comorbidities in gout - hypertension, chronic kidney disease (CKD), and nephrolithiasis - is very high."
    explanation: >-
      Establishes CKD as one of the highly prevalent renal comorbidities of
      gout, corroborating the pairing at the population level.
  pathophysiology:
  - name: Impaired renal urate excretion and hyperuricemia
    description: >-
      Loss of functioning nephrons reduces net urate excretion, raising serum
      urate toward the saturation point at which monosodium urate crystals
      deposit in and around joints.
    biological_processes:
    - preferred_term: urate metabolic process
      term:
        id: GO:0046415
        label: urate metabolic process
    evidence:
    - reference: PMID:23318701
      reference_title: The kidney in hyperuricemia and gout.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "baseline SUA appears to be set by the net balance of absorption and secretion across epithelial cells in the kidney and intestine."
      explanation: >-
        States that the serum urate set point is determined by renal and
        intestinal handling, the process this node represents.
  - name: Serum urate as the graded driver of incident gout in CKD
    description: >-
      Within a CKD population that is already hyperuricemic, the risk of
      developing clinical gout continues to scale with serum urate, indicating
      the urate level and not merely the presence of kidney disease is what
      drives crystal deposition.
    evidence:
    - reference: PMID:41608294
      reference_title: The Incidence and Risk Factors of Gout in Non-dialysis Chronic Kidney Disease Patients With Asymptomatic Hyperuricemia.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Notably, each 1 mg/dL increase in baseline serum urate levels was associated with a 29% higher risk of developing gout, with a HR of 1.29 (95% CI, 1.14-1.46)."
      explanation: >-
        Quantifies the graded, per-unit effect of serum urate on incident gout
        within a CKD cohort, supporting urate as the mediating variable.
    - reference: PMID:41608294
      reference_title: The Incidence and Risk Factors of Gout in Non-dialysis Chronic Kidney Disease Patients With Asymptomatic Hyperuricemia.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The relatively low gout incidence in CKD stage 5, particularly in patients receiving hemodialysis, compared with CKD stages 3-4, may be due to reduced inflammatory cytokine production."
      explanation: >-
        The same cohort found gout less often at stage 5 than at stages 3-4,
        with lower creatinine an independent predictor. This does not
        contradict urate as the driver: it shows that kidney-disease severity
        is not the graded variable, and the authors attribute the inverse
        gradient partly to blunted inflammatory responses in advanced CKD (see
        entry notes).

- description: >-
    Reverse-direction hypothesis, recorded because it is widely assumed and not
    supported: that hyperuricemia and gout are themselves nephrotoxic, so that
    gout drives incident CKD and lowering urate would protect renal function.
    A 13-year population-based cohort comparing urate-lowering therapy users
    with matched non-users among gout patients found no difference in incident
    CKD. The negative result does not exclude a urate effect on established CKD
    progression, which the cited study did not test, but it does undercut the
    simple causal loop and is why this entry is directed rather than
    BIDIRECTIONAL.
  evidence:
  - reference: PMID:34104091
    reference_title: Urate-lowering Therapy and Chronic Kidney Disease Development in Patients with Gout.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "This population-based cohort study indicated that ULT is not associated with lower risk of CKD development."
    explanation: >-
      Removing the hyperuricemia did not reduce incident CKD in gout patients
      (adjusted hazard ratio 0.97, 95% CI 0.88-1.07), arguing against urate as
      a causal driver of new-onset kidney disease.

association_signals:
- source: LITERATURE
  method: LITERATURE_ASSOCIATION
  population: >-
    771 ambulatory non-dialysis patients with stage 3-5 chronic kidney disease
    and asymptomatic hyperuricemia (serum urate >=7.0 mg/dL) and no prior gout,
    single centre, followed 2010-2023 with a median follow-up of 47 months and
    incident gout confirmed by rheumatology specialists.
  directionality: A_BEFORE_B
  effect_direction: RISK
  mapping_notes: >-
    The cohort is restricted to CKD patients who are already hyperuricemic, so
    the rate is conditioned on the intermediate step of the mechanism and is
    higher than it would be across unselected CKD. Single-centre and
    retrospective, as the authors note.
  statistics:
    metrics:
    - metric_type: INCIDENCE_RATE
      metric_value: 41.9
      notes: >-
        Incident gout per 1,000 person-years; 140 of 771 patients (18.2%) over
        a median 47 months. The denominator is a CKD population followed
        forward with gout excluded at baseline, which is what the directed
        A_BEFORE_B claim requires.
    evidence:
    - reference: PMID:41608294
      reference_title: The Incidence and Risk Factors of Gout in Non-dialysis Chronic Kidney Disease Patients With Asymptomatic Hyperuricemia.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "gout developed in 140 (18.2%) patients (incidence rate, 41.9 cases per 1,000 person-years)."
      explanation: >-
        Measures incident gout prospectively within a defined CKD cohort,
        supporting CKD as an antecedent state for gout rather than a
        co-diagnosis.

Source:GitHub